Motor neuron disease (MND) is characterised by the degeneration of motor neurons in the brain and spinal cord that leads to muscle weakness, wasting, and paralysis. It is an inevitably lethal disease with a lifetime risk of ~ 1 in 400 Australians. Interestingly, some people with MND also develop frontotemporal dementia (FTD), suggesting that the two diseases are related. Frontotemporal dementia (FTD) is characterised by the loss of neurons in the brain, which causes changes in personality, emotional state, and language difficulties, accounting for 1 in 20 cases of dementia. The incidence of both of these diseases is increasing and there are no effective treatments that slow or stop the progression of either of these diseases.
One of the first events, at the molecular level, involved in 97% of MND and 50% of FTD cases is the abnormal build-up of a protein called TDP-43 in motor neurons. TDP-43 proteins stick together to form toxic clumps and over time the accumulation of these TDP-43 clumps leads to the death of neurons in MND/FTD. Therefore, one potential therapeutic strategy is to prevent this toxic process of TDP-43 clumping. Unfortunately, there is currently a limited understanding of how TDP-43 clumps in neurons and why it is toxic. The primary aim of this project is to identify the cellular pathways that increase or decrease TDP-43 clumping and its associated toxicity to neurons. This project will use revolutionary gene editing technology to scan every gene in the human genome to identify the genes involved in triggering TDP-43 clumping. This is extremely important because it will broaden the scope of new druggable targets to treat people living with MND and FTD. This approach has great potential to put us on the path towards more effective treatments for people living with MND and FTD.